Lamivudine/tenofovir disoproxil fumarate - Micro Labs
Alternative Names: HA620Latest Information Update: 23 Feb 2022
At a glance
- Originator Micro Labs
- Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Phosphonic acids; Purines; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered HIV-1 infections
Most Recent Events
- 23 Feb 2022 Lamivudine/tenofovir disoproxil fumarate is not yet available for HIV-1 infections in USA (PO)
- 06 Feb 2018 Chemical structure information added
- 25 Jan 2018 US FDA tentatively approves NDA for Lamivudine/tenofovir disoproxil fumarate in HIV-1 infections (Combination therapy with antiretrovirals)